Successful cure of a patient with urosepsis using a combination of extracorporeal membrane oxygenation and continuous renal replacement therapy: A case report and literature review.
10.1016/j.cjtee.2020.09.006
- Author:
Chun-Yan ZHU
1
;
Ai-Jun PAN
2
;
Qing MEI
1
;
Ting CHEN
3
Author Information
1. Department of Critical Care Medicine, The First Affiliated Hospital of USTC, Hefei 230032, China.
2. Department of Critical Care Medicine, The First Affiliated Hospital of USTC, Hefei 230032, China. Electronic address: aijunpan@fsyy.ustc.edu.cn.
3. Department of Critical Care Medicine, The Second People's Hospital of Hefei, Hefei 230009, China.
- Publication Type:Review
- Keywords:
Continuous renal replacement therapy;
Extracorporeal membrane oxygenation;
Refractory;
Sepsis
- MeSH:
Aged;
Extracorporeal Membrane Oxygenation/methods*;
Female;
Humans;
Lasers, Solid-State/adverse effects*;
Lithotripsy, Laser/methods*;
Postoperative Complications/therapy*;
Renal Replacement Therapy/methods*;
Shock, Septic/therapy*;
Treatment Outcome;
Urinary Tract Infections/therapy*;
Urolithiasis/surgery*
- From:
Chinese Journal of Traumatology
2020;23(6):372-375
- CountryChina
- Language:English
-
Abstract:
Holmium laser lithotripsy (HLL) is one of the common surgical methods for urolithiasis. It causes minor surgical trauma, but complications are not rare. Extracorporeal membrane oxygenation (ECMO) treatment of sepsis is common, but venoarterial (VA)-ECMO treatment of urosepsis has not been reported yet. In this article, we reported a 67-year-old female patient with refractory septic shock caused by HLL under percutaneous nephroscope, involving breathing, heart, kidney and other organs, and organs support treatment was ineffective for the patient. Finally, we successfully treated the patient under VA-ECMO with continuous renal replacement therapy (CRRT). Combined ECMO and CRRT may provide a solution for addressing refractory sepsis. Here we present the case and review relevant literature, so as to provide a treatment strategy for patients with refractory urogenic sepsis and to reduce the mortality rate.
